Third primary SARS-CoV-2 mRNA vaccines enhance antibody responses in most patients with haematological malignancies

SARS-CoV-2 vaccination has shown reduced efficacy in patients with haematological malignancies. Here, the authors show that a third vaccine is able to enhance SARS-CoV-2 antibody responses in most cases in a cohort of 381 patients with haematological malignancies.

Bibliographic Details

Published in:	Nature Communications
Main Authors:	Lucy B. Cook, Gillian O’Dell, Eleni Vourvou, Renuka Palanicawandar, Sasha Marks, Dragana Milojkovic, Jane F. Apperley, Sandra Loaiza, Simone Claudiani, Marco Bua, Catherine Hockings, Donald Macdonald, Aris Chaidos, Jiri Pavlu, Nichola Cooper, Sarah Fidler, Paul Randell, Andrew J. Innes
Format:	Article
Language:	English
Published:	Nature Portfolio 2022-11-01
Online Access:	https://doi.org/10.1038/s41467-022-34657-z